Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05257109 · ClinicalTrials.gov registry record · NA
Water Content in E-Liquids
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 31
- Enrollment target
NCT05257109: Completed NA study, sponsored by Yale University.
NCT05257109 is a NA study that has completed, run by Yale University. The registered enrollment target is 31 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05257109, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
Study Summary
This study looks at the effect of manipulating the water concentration of certain e-liquids on sensory perception.
Primary Outcome
Change in irritation at each water level as measured by the computerized Generalized Labeled Magnitude Scale (gLMS). Participants will self-report their responses using a computer mouse to indicate where on the scale response falls. The Generalized Labeled Magnitude Scales (gLMS) are category ratio scales with seven semantic labels: "no sensation", "barely detectable", "weak", "moderate", "strong", "very strong", and "strongest imaginable", positioned quasi-logarithmically as per empirically det
Interventions
- OTHER Water Concentration 1
- OTHER Water Concentration 2
- OTHER Water Concentration 3
- OTHER Water Concentration 4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2022-08-01 |
| Est. Completion | 2023-03-10 |
| Phase | NA |
What the finished NCT05257109 record still lists
NCT05257109 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 4 interventions - of which Water Concentration 1 is the first listed.
NCT05257109 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05257109 about?
NCT05257109 is a clinical study titled "Water Content in E-Liquids". This study looks at the effect of manipulating the water concentration of certain e-liquids on sensory perception.
What is the current status of trial NCT05257109?
This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2022-08-01. Estimated completion is 2023-03-10.
What interventions are being tested in trial NCT05257109?
The interventions under investigation include: Water Concentration 1 (OTHER), Water Concentration 2 (OTHER), Water Concentration 3 (OTHER), Water Concentration 4 (OTHER).
Who is sponsoring clinical trial NCT05257109?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05257109's enrollment target sits among peer trials
31 1592nd of 2000 higher than 408 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI